Novel therapeutic options in the inflammatory bowel disease world

被引：6

作者：

Noble, A. ^{[1
]}

Baldassano, R. ^{[1
]}

Mamula, P. ^{[1
]}

机构：

[1] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr,Div GI & Nutr, Philadelphia, PA 19104 USA

来源：

DIGESTIVE AND LIVER DISEASE | 2008年 / 40卷 / 01期

关键词：

biologics; children; Crohn's disease; helminthes; inflammatory bowel disease; leukocyte apheresis; probiotics; stem cell transplantation; ulcerative colitis;

D O I：

10.1016/j.dld.2007.07.169

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Advances in the understanding of the pathogenesis of inflammatory bowel disease have encouraged the development of many new therapies targeted at specific and non-specific mediators of the inflammatory bowel disease inflammatory pathway. The role of these therapies, including novel anti-tumour necrosis factor-a agents, anti-adhesion molecules, recombinant cytokines, myeloid growth factors, helminths, and probiotics, in the management of paediatric onset inflammatory bowel disease is promising and warrants further investigation. (c) 2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

引用

收藏

页码：22 / 31

页数：10

相关论文

共 81 条

[1] A randomized, double-blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease [J].

Bousvaros, A ;

Guandalini, S ;

Baldassano, RN ;

Botelho, C ;

Evans, J ;

Ferry, GD ;

Goldin, B ;

Hartigan, L ;

Kugathasan, S ;

Levy, J ;

Murray, KE ;

Oliva-Hemker, M ;

Rosh, JR ;

Tolia, V ;

Zholudev, A ;

Vanderhoof, JA ;

Hibberd, PL .

INFLAMMATORY BOWEL DISEASES, 2005, 11 (09) :833-839

[2] High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease [J].

Burt, RK ;

Traynor, A ;

Oyama, Y ;

Craig, R .

BLOOD, 2003, 101 (05) :2064-2066

[3] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Rutgeerts, Paul ;

Enns, Robert ;

Hanauer, Stephen B. ;

Panaccione, Remo ;

Schreiber, Stefan ;

Byczkowski, Dan ;

Li, Ju ;

Kent, Jeffrey D. ;

Pollack, Paul F. .

GASTROENTEROLOGY, 2007, 132 (01) :52-65

[4] Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease [J].

Colombel, JF ;

Rutgeerts, P ;

Malchow, H ;

Jacyna, M ;

Nielsen, OH ;

Rask-Madsen, J ;

Van Deventer, S ;

Ferguson, A ;

Desreumaux, P ;

Forbes, A ;

Geboes, K ;

Melani, L ;

Cohard, M .

GUT, 2001, 49 (01) :42-46

[5]

COLOMBEL JF, 2007, LONG TERM TOLERABILI

[6]

COLOMBEL JF, 2007, GASTROENTEROLOGY S, V2, P132

[7] Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis [J].

Creed, TJ ;

Norman, MR ;

Probert, CSJ ;

Harvey, RF ;

Shaw, IS ;

Smithson, J ;

Anderson, J ;

Moorghen, M ;

Gupta, J ;

Shepherd, NA ;

Dayan, CM ;

Hearing, SD .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (01) :65-75

[8] Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease [J].

Creed, TJ ;

Probert, CSJ ;

Norman, MN ;

Moorghen, M ;

Shepherd, NA ;

Hearing, SD ;

Dayan, CM .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (10) :1435-1442

[9]

DESLANDERS C, 2006, GASTROENTEROLOGY, V130, pSE

[10] Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor [J].

Dieckgraefe, BK ;

Korzenik, JR .

LANCET, 2002, 360 (9344) :1478-1480

← 1 2 3 4 5 6 7 8 9 →